On 10 May 2017, the FDA further expanded its approval as a first-line treatment in combination with pemetrexed and carboplatin for metastatic non-squamous NSCLC without EGFR or ALK mutation, irrespective of PDL-1 expression (Category 1 and preferred if PD-L1 expression 1–49%; Category 1 if PD-L1 expression is ≥ 50%). Here, CD274 is linked to non-small cell lung carcinoma.